fda d.i.s.c.o. burst edition: fda approvals of enhertu (fam-trastuzumab deruxtecan-nxki) for unr...
Published 5 months ago • 49 plays • Length 7:01
Download video MP4
Download video MP3
Similar videos
-
3:31
fda d.i.s.c.o. burst edition: fda approval of enhertu (fam-trastuzumab deruxtecan-nxki) for unres...
-
4:31
fda d.i.s.c.o. burst edition: fda approval of enhertu (fam-trastuzumab deruxtecan-nxki) for adult...
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
2:07
fda clears new device for ear tube surgeries
-
7:18
advancements in non-small cell lung cancer
-
33:32
genexus dx integrated sequencer (ce-ivd) - nucleic acid to ngs report in as little as 24 hours
-
6:06
meet our faculty | uw radiology residency program
-
1:41
shadow 12sf system
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
8:41
cilta-cel for myeloma, enhertu for her2-positive solid tumors, fanapt for bipolar, zevtera for...
-
10:55
fda approval in myeloma, label update in her2 breast cancer, and more
-
4:13
case of the week: breast nodular fasciitis
-
0:54
dr. ferris on a trial testing adu-s100/miw815/pembrolizumab in head and neck cancer
-
11:00
fda approval in her2 breast cancer, priority review in nsclc, and more
-
1:12
ask unmc! how dangreous is radon in nebraska homes?
-
2:07
the impact of updated fda regulation on breast density notification | uw medicine
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
7:57
fda approvals in breast cancer and melanoma, disappointing results in hnscc, and more
-
11:13
fda approval in her2 early breast cancer, fast track designation in tnbc, and more
-
2:43
study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer
-
2:21
fda approves foundationone®cdx as companion diagnostic
Clip.africa.com - Privacy-policy